Abstract
AbstractUnderstanding the acceptability of long-acting injectable antiretroviral therapy (LAI-ART) among people with HIV (PWH), especially priority populations, is essential for effective implementation. We conducted semi-structured interviews with patients in three Ryan White-funded HIV clinics in San Francisco, Chicago, and Atlanta. We employed maximal variation sampling across age, gender, race, ethnicity, and time living with HIV and oversampled for individuals with suboptimal clinical engagement. An 8-step hybrid deductive and inductive thematic analysis approach guided data analysis. Between August 2020 and July 2021, we conducted 72 interviews. Median age was 46 years; 28% were ciswomen, 7% transwomen, 44% Black/African-American and 35% Latinx, 43% endorsed a psychiatric diagnosis, 35% were experiencing homelessness/unstable housing, and 10% had recent substance use. Approximately 24% were sub-optimally engaged in care. We observed a spectrum of LAI-ART acceptability, ranging from enthusiasm to hesitancy to rejection. We also characterized four emergent orientations towards LAI-ART: innovator, pragmatist, deliberator, and skeptic. Overall, the majority of participants expressed favorable initial reactions towards LAI-ART. Most approached LAI-ART pragmatically, but acceptability was not static, often increasing over the course of the interview. Participants considered their HIV providers as essential for affirming personal relevance. HIV stigma, privacy concerns, and medical mistrust had varied impacts, sometimes facilitating and other times hindering personal relevance. These findings held across priority populations, specifically young adults, cis/trans women, racial/ethnic minorities, and individuals with suboptimal clinical engagement. Further research is needed to explore the transition from hypothetical acceptance to uptake and to confirm the actual benefits and drawbacks of this treatment.
Funder
Foundation for the National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2023. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv.
2. Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844–5. https://doi.org/10.1001/jama.2019.1343.
3. Centers for Disease Control and Prevention. Ending the HIV epidemic in the US: EHE pillars. 2023. https://www.cdc.gov/endhiv/about-ehe/pillars.html.
4. Centers for Disease Control and Prevention. HIV Surveillance Supplemental Report: monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas 2021;28(4). 2023. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
5. Benator DA, Elmi A, Rodriguez MD, Gale HB, Kan VL, Hoffman HJ, et al. True durability: HIV virologic suppression in an urban clinic and implications for timing of intensive adherence efforts and viral load monitoring. AIDS Behav. 2015;19(4):594–600. https://doi.org/10.1007/s10461-014-0917-6.